Award
NIH Reporter #4R44AI186932-02
Enhanced Seasonal Influenza Vaccine Targeting Variable and Conserved Antigens
Recipient
ORLANCE, INC.
Award Amount
$1,000,000.00
Ceiling
$1,000,000.00
Awarded
August 31, 2026
Identifier
4R44AI186932-02
Award for developing a novel DNA-based influenza vaccine focusing on rapid manufacturing and improved immune response, targeting vulnerable populations.
Description
This project aims to develop a novel influenza vaccine using DNA technology, with a focus on rapid manufacturing and enhanced immune responses, especially in vulnerable populations. The project involves comparison of different DNA formulations and delivery methods, with potential progression to human clinical trials.